Arcellx had its Relative Strength (RS) Rating upgraded from 70 to 76 Tuesday — a welcome improvement, but still below the 80 or higher score you look for.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily tracks price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best stocks typically have an RS Rating of at least 80 as they begin their largest price moves. See if Arcellx can continue to rebound and hit that benchmark.
Arcellx is not currently showing a potential buy point. See if the stock goes on to build a chart pattern that could kick off a new climb.
Arcellx posted 0% earnings growth last quarter. Revenue gains came in at -76%. Look for the next report on or around May 8.
Arcellx holds the No. 192 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
